Xeomin vs Botox: Same 20/24/40/64-Unit Upper Face, Different US Labels

If you are choosing between Xeomin and BOTOX Cosmetic for facial wrinkle reduction, med-spa consultations frequently pitch Xeomin as "naked Botox"—promising the exact same 20-unit glabellar pattern, zero unnecessary bacterial proteins, a lower risk of developing resistance, a softer and more natural look, and a lower price tag per unit.

When you examine the official United States Food and Drug Administration (FDA) prescribing labels for both biologics, the clinical reality is far more specific:

1. Identical Upper-Face Dosing Geometry: For upper-facial lines, both products share the exact same labeled unit maps: 20 Units for frown lines (11s), 24 Units for crow's feet, 20 Units for horizontal forehead lines (labeled only in conjunction with 20 Units of glabella, totaling 40 Units), and a maximum combined ceiling of 64 Units when all three upper-face areas are treated simultaneously.
2. The Major Indication Gap (Platysma Neck Bands): BOTOX Cosmetic holds FDA approval for four aesthetic indications in adults, including moderate to severe platysma neck bands (26, 31, or 36 Units). In contrast, Xeomin is FDA-approved for upper facial lines only; using Xeomin in the neck or lower face is off-label in the United States.
3. Strict Unit Non-Interchangeability: Both package inserts carry explicit warnings that botulinum toxin potency units cannot be compared or converted using a universal ratio. A 1:1 glabellar conversion is a clinical habit matching trial totals, not an FDA-established equivalence standard.
4. Mismatched Clinical Trial Endpoints: Clinic websites frequently claim Botox is "80% effective" while Xeomin is "48% to 60% effective." This is a statistical error comparing Botox's single-investigator "none or mild" endpoint with Xeomin's composite hurdle requiring simultaneous 2-grade improvement by both clinician and patient.
5. The "Naked Toxin" Marketing Claim: Xeomin is formulated as pure 150 kDa neurotoxin without complexing accessory proteins, allowing room-temperature storage. While this is an authentic biochemical fact, clinical trials have not demonstrated superior longevity, faster onset, or a "more natural" aesthetic outcome over Botox in cosmetic patients.
6. Mandatory Forehead Coupling: Both labels mandate that horizontal forehead lines must be treated alongside the glabella to prevent isolated frontalis muscle depression and secondary brow ptosis.

---

Direct Answer: How Do Xeomin and Botox Compare?

For a patient deciding between Xeomin and BOTOX Cosmetic:

• For frown lines, crow's feet, and forehead: Both are first-line, FDA-approved neuromodulators following identical anatomical injection patterns (20 U glabella, 24 U crow's feet, 40 U forehead + glabella, 64 U combined). Peak assessment in both labels is at Day 30. Typical practice duration is 3 to 4 months. Neither label proves a faster 2-to-4-day onset for one brand over the other.
• For neck rejuvenation: If you are treating vertical platysmal bands, BOTOX Cosmetic is FDA-approved on-label for this indication. Xeomin is not approved for platysma bands in the US.
• Pricing reality: Xeomin typically retails for $10 to $16 per unit, while BOTOX Cosmetic typically retails for $12 to $20+ per unit. For a standard 20-unit glabellar session, Xeomin usually costs $200 to $320, compared to $240 to $400+ for Botox.
• Resistance and antibodies: True neutralizing-antibody failure is uncommon at labeled aesthetic doses. Switching to Xeomin will not "reset" a short duration that is actually fast metabolism, under-dosing, or deep static creases. A lower immunogenicity advantage in cosmetic use is not established by a large aesthetic head-to-head.
• Storage and reconstitution: Unopened Xeomin may be stored at or below 25°C. Unopened BOTOX Cosmetic is stored refrigerated at 2°C to 8°C and should not be frozen. Once reconstituted, both labels require use within 24 hours.

---

What Is Actually FDA-Approved for Each Product?

The regulatory status and approved anatomical indications of botulinum toxins reflect extensive clinical trial programs evaluated by the FDA's Center for Drug Evaluation and Research (CDER).

                     [FDA Aesthetic Indications Matrix]

  Anatomical Indication              BOTOX Cosmetic        XEOMIN
  ────────────────────────────────   ──────────────        ──────
  Moderate to Severe Glabellar 11s   FDA-Approved (2002)   FDA-Approved (2011)
  Lateral Canthal Lines (Crow's Feet) FDA-Approved (2013)   FDA-Approved (2024)*
  Horizontal Forehead Lines          FDA-Approved (2017)   FDA-Approved (2024)*
  Platysma Neck Bands                FDA-Approved (2024)   Off-Label
  Simultaneous Upper-Face (64 Units) FDA-Approved (2017)   FDA-Approved (2024)*
  *Approved under the Upper Facial Lines (UFL) simultaneous indication label.

BOTOX Cosmetic (onabotulinumtoxinA)

Manufactured by Allergan Aesthetics (an AbbVie company), BOTOX Cosmetic (BLA 103000, SPL effective October 18, 2024) is the reference botulinum toxin type A biologic in the US. It is FDA-approved in adults for four aesthetic indications:

1. Glabellar Lines: 20 Units total (5 injection sites of 4 U each: 1 procerus, 2 medial corrugators, 2 lateral corrugators).
2. Lateral Canthal Lines (Crow's Feet): 24 Units total (12 U per side across 3 injection sites of 4 U each); see Botox for crow's feet units and approved toxins.
3. Forehead Lines: 20 Units total (injected across 5 sites), labeled to be administered only in conjunction with glabellar treatment (20 U + 20 U = 40 U total) to prevent eyebrow ptosis.
4. Platysma Bands: 26, 31, or 36 Units depending on anatomical band pattern (26 U for 1 band per side; 31 U for 2 bands on one side and 1 on the other; 36 U for 2 bands per side); see Botox for platysma bands and neck rejuvenation.

XEOMIN (incobotulinumtoxinA)

Manufactured by Merz Pharmaceuticals in Germany and marketed by Merz Aesthetics, XEOMIN (BLA 125360, SPL effective July 10, 2026) was first approved for glabellar lines in 2011. In July 2024, the FDA approved Merz's supplemental Biologics License Application (sBLA) expanding Xeomin's aesthetic indication to Upper Facial Lines (UFL):

• Temporary improvement in the appearance of moderate to severe upper facial lines (glabellar lines, horizontal forehead lines, and lateral canthal lines) in adult patients.

Xeomin's aesthetic label is strictly bounded to the upper face. The package insert contains no aesthetic indication for platysma bands, masseter reduction, or perioral lines. For an overview of the single-product profile, explore our Xeomin patient guide. For a broader cross-toxin landscape, review all six FDA-approved neurotoxins compared.

---

Are Xeomin and Botox Units Interchangeable?

A common assumption among aesthetic patients is that "1 unit of Xeomin" is an exact scientific duplicate of "1 unit of Botox," functioning like milligrams of ibuprofen or acetaminophen.

                    [The Non-Interchangeability Standard]

  BOTOX Cosmetic (onabotulinumtoxinA) ──► Allergan Mouse LD50 Assay Units
  XEOMIN (incobotulinumtoxinA)         ──► Merz Proprietary Assay Units
  DYSPORT (abobotulinumtoxinA)        ──► Speywood Potency Units (50 U Glabella)
  DAXXIFY (daxibotulinumtoxinA-lanm)  ──► Revance Potency Units (40 U Glabella)

The Potency Assay Warning

Section 5.1 of both the BOTOX Cosmetic and XEOMIN official prescribing information states explicitly:

"The potency units of [Drug] are specific to the preparation and assay method utilized. They are not interchangeable with other preparations of botulinum toxin products and, therefore, units of biological activity of [Drug] cannot be compared to or converted into units of any other botulinum toxin products assessed with any other specific assay method."

Each biologic manufacturer measures potency by determining the median lethal dose (LD50) in laboratory mice. Because assay parameters—including dilution buffers, animal strains, pH stabilization, and vehicle proteins—differ between laboratories, a "Unit" is an internal biological activity measurement rather than an international standardized unit.

The 1:1 Glabellar Practice Convention

In clinical practice, injectors dose Xeomin at a 1:1 unit ratio with Botox in the glabella (20 Units of Xeomin = 20 Units of Botox).

This convention is clinically sound because both pivotal FDA trial programs evaluated the exact same 20-Unit, 5-injection-site pattern. However, this 1:1 habit is clinical practice matching labeled totals, not an FDA-approved conversion factor. It does not mean units convert 1:1 in off-label areas like masseter slimming or micro-toxin mesotherapy.

---

Why You Cannot Rank Xeomin 48–60% vs. Botox 80% from Trial Data

When patients compare neuromodulators online, clinic comparison tables frequently display:

• BOTOX Cosmetic: "80% Response Rate"
• XEOMIN: "48% to 60% Response Rate"

This comparison is a classic example of cross-trial bias that conflates fundamentally different statistical responder definitions.

                   [Comparing Pivotal Trial Endpoints]

  Xeomin Glabellar Trials (GL-1 / GL-2)            Botox Glabellar Pivotal Trials
  ─────────────────────────────────────            ──────────────────────────────
  • Cohort: N = 547 (366 Xeomin, 181 Placebo)      • Cohort: N = 537 (405 Botox, 132 Placebo)
  • Primary: COMPOSITE ≥ 2-grade improvement       • Primary: INVESTIGATOR-ONLY "None or Mild"
  • Evaluators: BOTH Investigator AND Subject      • Evaluator: Single Clinician Assessment
  • Results: 60% (GL-1) & 48% (GL-2) vs. 0% Placebo • Results: 80% (325/405) vs. 3% (4/132) Placebo

Xeomin's Composite 2-Grade Co-Primary Endpoint

In Xeomin's pivotal glabellar studies (GL-1 and GL-2, evaluated in 547 subjects):

• Treatment success was defined as a composite endpoint: a subject had to achieve at least a 2-grade improvement from baseline at maximum frown on Day 30 on the 4-point Facial Wrinkle Scale (FWS) as independently rated by the Investigator AND the Subject.
• If the investigator observed a 2-grade improvement but the patient noted only a 1-grade change, the subject was categorized as a treatment failure.
• Under this strict double-evaluator composite hurdle, the Xeomin label reports response rates of 60% (111 of 184) in Study GL-1 and 48% (87 of 182) in Study GL-2 (versus 0% in placebo).
• The same Xeomin table also reports investigator-only success of 77% (GL-1) and 71% (GL-2). Those investigator-only figures sit closer to Botox's investigator-only 80% than the composite 60%/48% does — which is why ranking the composite against Botox's investigator endpoint is a category error.

Botox's Investigator "None or Mild" Endpoint

In BOTOX Cosmetic's historical glabellar registration trials (under BLA 103000):

• The primary efficacy endpoint was defined as an investigator rating of severity of none or mild at maximum frown on Day 30.
• Under this single-evaluator threshold, Botox demonstrated an 80% response rate (325 of 405) compared to 3% (4 of 132) for placebo.

A single clinician determining that wrinkles have become "mild" is a very different mathematical hurdle than requiring simultaneous agreement between patient and doctor on a 2-step improvement from severe to mild. Neither label proves superior clinical line-smoothing over the other.

Xeomin Upper Facial Lines (UFL) Trials 1071 & 1070

For its July 2024 simultaneous three-area upper-face approval, Merz conducted two Phase 3 trials (NCT04594213 / Trial 1071 and NCT04622254 / Trial 1070) enrolling 730 adults:

• In Trial 1071, subjects receiving the full 64-Unit simultaneous dose (20 U GL + 20 U HFL + 24 U LCL) achieved Day-30 composite treatment success of 53% in glabella, 67% in horizontal forehead, and 53% in lateral canthal lines, compared to 0% in placebo.

---

Does "No Accessory Proteins" Make Xeomin Last Longer or Look More Natural?

The defining marketing differentiator for Xeomin is that it is a "pure" or "naked" neurotoxin.

                    [Molecular Architecture Comparison]

  Product            Molecular Weight   Structure                 Excipients (per 100 U Vial)
  ────────────────   ────────────────   ───────────────────────   ───────────────────────────
  BOTOX Cosmetic     ~900 kDa           150 kDa Neurotoxin +      0.5 mg Human Albumin +
                                        750 kDa Accessory Protein 0.9 mg Sodium Chloride
  XEOMIN             ~150 kDa           Pure 150 kDa Neurotoxin   1.0 mg Human Albumin +
                                        (No Accessory Proteins)   4.7 mg Sucrose

The Biochemical Reality

During bacterial synthesis by Clostridium botulinum, the active 150 kDa neurotoxin chain naturally aggregates with complexing hemagglutinin and non-hemagglutinin accessory proteins.

• Botox Cosmetic retains these accessory proteins in a ~900 kDa molecular complex.
• Xeomin undergoes an additional chromatographic purification step that strips away all accessory proteins, isolating the pure 150 kDa active core.

Because Xeomin contains no complexing proteins, it does not require cold-chain refrigeration prior to reconstitution and can be stored at room temperature (up to 25°C / 77°F).

Clinical Implications in Aesthetic Practice

1. Diffusion and Dissociation: In physiological tissue (pH ~7.4), the 900 kDa Botox complex dissociates into the 150 kDa active neurotoxin within less than one minute after injection. The accessory proteins do not affect diffusion kinetics or tissue spread.
2. Longevity at Labeled Doses: Removing accessory proteins does not extend duration. Both Xeomin and Botox Cosmetic exhibit identical clinical durations of 3 to 4 months at standard doses; see how long Xeomin lasts and how long Botox lasts.
3. "More Natural" Facial Expression: Some med spas claim Xeomin produces a "softer, more natural look." This is an aesthetic outcome determined entirely by injector dosing and micro-placement, not by the molecular weight of the toxin vial.
4. Immunogenicity and Resistance: In therapeutic neurology (where patients receive 300 to 800+ units per session for limb spasticity or cervical dystonia), complexing proteins are discussed as a possible immunogenicity factor. In cosmetic medicine (typical labeled doses 20 to 64 units, months apart), primary antibody-mediated resistance is uncommon for both products. Neither aesthetic label proves a neutralizing-antibody rate below 0.5%, and switching brands is not a labeled reset for a short-lived result.

---

Upper-Face Treatment Protocols and Safety Boundaries

Treating the upper third of the face requires an appreciation of agonist-antagonist muscle dynamics between the frontalis (the sole brow elevator) and the glabellar/orbicularis complexes (brow depressors).

                 [Upper-Face Labeled Injection Architecture]

  Anatomical Zone         Target Muscle         Labeled Dose   Sites & Placement Rules
  ────────────────────    ───────────────────   ────────────   ──────────────────────────────────
  Glabellar Frown Lines   Procerus & Corrugator 20 Units       5 sites (4 U each); ≥1 cm above rim
  Crow's Feet (LCL)       Orbicularis Oculi     24 Units       6 sites (4 U/site; 3 per eye)
  Horizontal Forehead     Frontalis             20 Units       5 sites (4 U each; paired with GL)
  Combined Upper Face     All Three Zones       64 Units       Simultaneous labeled ceiling

The Forehead Ptosis Guardrail

Both the Botox and Xeomin prescribing labels mandate that horizontal forehead lines must be treated in conjunction with glabellar lines (20 U + 20 U = 40 U total). Treating the frontalis alone eliminates brow elevation while leaving the corrugators and procerus unopposed, pulling the eyebrows downward and creating severe brow heaviness or pseudoptosis.

Adverse Reactions and Boxed Warnings

Both products carry a class-wide FDA Boxed Warning regarding the distant spread of toxin effect. Symptoms such as generalized muscle weakness, diplopia, ptosis, dysphagia, dysphonia, and breathing difficulties are extremely rare at cosmetic doses.

In clinical trials, labeled adverse-reaction rates include:

• Eyelid ptosis: 3% in BOTOX Cosmetic glabellar trials.
• Brow ptosis: 2% in BOTOX Cosmetic forehead studies; 0.7% in Xeomin UFL trials.
• Headache: 9% in BOTOX Cosmetic forehead trials; 5% vs 2% placebo in Xeomin glabellar trials. Xeomin UFL bruising was 2% vs 1% placebo.
• Injection-site bruising: listed among Xeomin UFL events occurring in more than 1% of subjects.

Those percents come from different trials and different anatomic programs. They are not a head-to-head ranking.

Labeled Contraindications

Both labels contraindicate treatment in:

• Known hypersensitivity to any botulinum toxin product or formulation component (both contain human albumin; Xeomin contains sucrose).
• Infection at the proposed injection site.

Neuromuscular junction disease (myasthenia gravis, Lambert-Eaton, ALS) and pregnancy or breastfeeding are warnings / use-in-specific-populations issues, not the two labeled contraindications. Safety in pregnancy is not established; patients with NMJ disease can have exaggerated weakness. Those are reasons to involve a clinician, not extra boxed contraindications.

---

Cost Comparison: How Much Do 20 to 64 Units Cost?

Because both Xeomin and BOTOX Cosmetic follow identical dosing maps, financial comparisons are transparent:

                  [Cost Math: Xeomin vs. BOTOX Cosmetic]

  Treatment Scope          Required Units   Typical XEOMIN Cost    Typical BOTOX Cost
  ──────────────────────   ──────────────   ───────────────────    ──────────────────
  Frown Lines (11s) Only   20 Units         $200 – $320            $240 – $400
  Crow's Feet Only         24 Units         $240 – $380            $288 – $480
  Forehead + Glabella      40 Units         $400 – $640            $480 – $800
  Full Upper Face (All 3)  64 Units         $640 – $1,020          $768 – $1,280+
  Physician Benchmark*     Mixed Areas      $697                   $697
  *(ASPS 2023 Member-Surgeon Average Procedure Fee for Botulinum Toxin)

1. Per-Unit Market Pricing: Xeomin is generally priced $2 to $4 less per unit than Botox because Merz offers competitive wholesale pricing to aesthetic practices. For more on pricing frameworks, see how Botox is priced per unit vs. per area.
2. Loyalty rewards programs: Merz operates Xperience+ and Allergan operates Allē. Point values and rebate amounts change; check the current program terms rather than treating any dollar figure as a fixed savings.
3. Sister Neurotoxin Comparisons: For patients comparing other toxin brands, explore our analyses of Jeuveau vs. Botox, Daxxify vs. Botox, Botox vs. Dysport, and Xeomin vs. Jeuveau.

---

Frequently Asked Questions

Which lasts longer, Botox or Xeomin?

Neither product has proven superior longevity at standard FDA-approved doses. In clinical practice and randomized trials, both BOTOX Cosmetic and Xeomin last an average of 3 to 4 months in the upper face.

Why is Xeomin cheaper than Botox?

Xeomin is often priced $2 to $4 less per unit ($10 to $16/unit vs. $12 to $20+/unit) because Merz Aesthetics offers competitive wholesale pricing to medical practices and does not have the massive direct-to-consumer advertising budget of Allergan.

Does Xeomin look more natural than Botox?

No chemical property makes Xeomin "more natural." Both products contain the identical active 150 kDa botulinum neurotoxin type A. A natural, expressive result depends entirely on the injector's anatomical precision and conservative dosing, not the brand on the vial.

Are Xeomin units the same as Botox units?

In clinical practice, injectors dose Xeomin and Botox at a 1:1 ratio for frown lines (20 units) because both labels share the same 20-unit dosing pattern. However, their potency assay units are proprietary and officially non-interchangeable under FDA labeling.

Can I use Xeomin on my neck bands?

Using Xeomin for platysma neck bands is off-label in the United States. If you are seeking an FDA-approved on-label neurotoxin for platysma bands, BOTOX Cosmetic is the only product currently approved for that indication (dosed at 26, 31, or 36 Units).

Who should avoid Xeomin?

Labeled contraindications are hypersensitivity to any botulinum toxin or formulation component (including human albumin or sucrose) and infection at the injection site. Neuromuscular junction disease and pregnancy or breastfeeding are labeled as warnings or unestablished-safety situations, not as additional contraindications. Platysma with Xeomin remains off-label.

---

Sources

• DailyMed — XEOMIN (incobotulinumtoxinA) Prescribing Information (FDA-Approved Label, Effective July 10, 2026): https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3f35d6e0-3450-4abc-a0da-cc7b277e7c6e
• DailyMed — BOTOX Cosmetic (onabotulinumtoxinA) Prescribing Information (FDA-Approved Label, Effective October 18, 2024): https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=485d9b71-6881-42c5-a620-a4360c7192ab
• Drugs@FDA — BLA 125360 Approval History (XEOMIN, Merz Pharmaceuticals): https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125360
• Drugs@FDA — BLA 103000 Approval History (BOTOX / BOTOX Cosmetic, Allergan/AbbVie): https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103000
• ClinicalTrials.gov — Safety and Efficacy of IncobotulinumtoxinA in Upper Facial Lines (Trial 1071 / NCT04594213): https://clinicaltrials.gov/study/NCT04594213
• ClinicalTrials.gov — Safety and Efficacy of IncobotulinumtoxinA in Upper Facial Lines (Trial 1070 / NCT04622254): https://clinicaltrials.gov/study/NCT04622254
• American Society of Plastic Surgeons (ASPS) — Botulinum Toxin Procedure Guide: https://www.plasticsurgery.org/cosmetic-procedures/botulinum-toxin
• Frevert J. — Pharmaceutical, Biological, and Clinical Properties of Botulinum Neurotoxin Type A Products (Drugs R D, 2015): https://pmc.ncbi.nlm.nih.gov/articles/PMC4359186/